Cited by 432Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and ResearchIntensive Care Unit Cognitive Disorders

Hypoglycemia and outcome in critically ill patients

Open access
Egi, Moritoki, Bellomo, Rinaldo, Stachowski, Edward, French, Craig J., Hart, Graeme K., Taori, Gopal, Hegarty, Colin, Bailey, Michael·2010·Mayo Clinic Proceedings

Abstract

Objective To determine whether mild or moderate hypoglycemia that occurs in critically ill patients is independently associated with an increased risk of death.Patients and methods Of patients admitted to 2 hospital intensive care units (ICUs) in Melbourne and Sydney, Australia, from January 1, 2000, to October 14, 2004, we analyzed all those who had at least 1 episode of hypoglycemia (glucose concentration, <81 mg/dL). The independent association between hypoglycemia and outcome was statistically assessed.Results Of 4946 patients admitted to the ICUs, a cohort of 1109 had at least 1 episode of hypoglycemia (blood glucose level, <81 mg/dL). Of these 1109 patients (22.4% of all admissions to the intensive care unit), hospital mortality was 36.6% compared with 19.7% in the 3837 nonhypoglycemic control patients (P<.001). Even patients with a minimum blood glucose concentration between 72 and 81 mg/dL had a greater unadjusted mortality rate than did control patients (25.9% vs 19.7%; unadjusted odds ratio, 1.42; 95% confidence interval, 1.12-1.80; P=.004.) Mortality increased significantly with increasing severity of hypoglycemia (P<.001). After adjustment for insulin therapy, hypoglycemia was independently associated with increased risk of death, cardiovascular death, and death due to infectious disease.Conclusion In critically ill patients, an association exists between even mild or moderate hypoglycemia and mortality. Even after adjustment for insulin therapy or timing of hypoglycemic episode, the more severe the hypoglycemia, the greater the risk of death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4065/mcp.2009.0394

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DPP-4 inhibitors plus low-dose basal insulin were as effective as basal-bolus insulin and were linked to less hypoglycemia and less treatment burden.

    “DPP-4 inhibitors combined with low-dose basal insulin have been similarly effective to basal-bolus insulin and associated with less hypoglycemia and less treatment burden.1351,1354–1357,1359”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1354]

    The Results and Clinical Implications passages discuss hypoglycemia and mortality in critically ill patients, not a comparison of DPP-4 inhibitors plus basal insulin with basal-bolus insulin. Searches for DPP-4 inhibitors, basal-bolus insulin, and treatment burden found no passage addressing the claimed effectiveness or advantages; page numbers were unavailable in our copy. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Oral DPP-4 inhibitors have been tested in RCTs in medical and surgical noncritically ill patients with mild hyperglycemia (admission glucose <180 mg/dL).

    “Oral DPP-4 inhibitors have been tested in RCTs in medical and surgical noncritically ill persons with mild hyperglycemia (admission glucose <180 mg/dL).1351,1354–1357”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1354]

    The Patients and Methods section describes patients in two intensive care units, not noncritically ill patients in trials of oral DPP-4 inhibitors. A search for DPP-4 inhibitors, sitagliptin, and the claimed admission-glucose threshold found no passage in our copy addressing those trials. The paper's 108–180 mg/dL figure is a glucose target, not an admission criterion. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [19]19. For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a .
  2. [34]34. moghissi es, Korytkowski mt, dinardo m, et al. american association of clinical endocrinologists and american diabetes association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15:353-369.
  3. [42]42. Herlein Ja, morgan da, phillips Bg, Haynes Wg, sivitz Wi. anteced- ent hypoglycemia, catecholamine depletion, and subsequent sympathetic neu- ral responses. Endocrinology. 2006;147:2781-2788.

Cited by

Sorted by citations

Authors
Egi, M., Bellomo, R., Stachowski, E., French, C. J., Hart, G. K., Taori, G., Hegarty, C., & Bailey, M.
Affiliations
  • Okayama University Hospital (JP)
  • Monash University (AU)
  • Westmead Hospital (AU)
  • Western Hospital (AU)
  • Austin Hospital (AU)
Corresponding author
Bellomo, Rinaldo
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2010-03
Volume
85
Issue
3
Pages
217-224
ISSN
0025-6196 (ISSN-L)
OpenAlex
W1999231148
Cited by
432
References
45
Citations by year
2026: 12 · 2025: 18 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 33 · 2020: 20 · 2019: 27 · 2018: 30 · 2017: 21 · 2016: 31 · 2015: 36 · 2014: 30 · 2013: 25 · 2012: 48
FWCI
31.37
Type
journal article
Language
en
Open access
Locations
  • Mayo Clinic Proceedings (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
Keywords
hypoglycemia, critically ill patients, intensive care unit, mortality, insulin therapy, cardiovascular mortality, infectious disease mortality, blood glucose
MeSH terms
Blood Glucose, Cause of Death, Female, Follow-Up Studies, Humans, Hypoglycemia, Intensive Care Units, Male, Middle Aged, Morbidity, Prognosis, Retrospective Studies, Risk Factors, Severity of Illness Index, Victoria, Survival Rate, Critical Illness, Hospital Mortality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review